Symbol="CRSP"
AssetType="Common Stock"
Name="Crispr Therapeutics AG"
Description="CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland."
CIK="1674416"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="BAARERSTRASSE 14, ZUG, CH"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="4057264000"
EBITDA="-538492032"
PERatio="None"
PEGRatio="0"
BookValue="23.52"
DividendPerShare="0"
DividendYield="0"
EPS="-6.57"
RevenuePerShareTTM="1.283"
ProfitMargin="0"
OperatingMarginTTM="-5.6"
ReturnOnAssetsTTM="-0.145"
ReturnOnEquityTTM="-0.256"
RevenueTTM="100258000"
GrossProfitTTM="-570697000"
DilutedEPSTTM="-6.57"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="105.38"
AnalystTargetPrice="84.31"
TrailingPE="-"
ForwardPE="23.36"
PriceToSalesRatioTTM="253.26"
PriceToBookRatio="2.011"
EVToRevenue="178.1"
EVToEBITDA="-3.434"
Beta="1.614"
num_52WeekHigh="84.1"
num_52WeekLow="38.94"
num_50DayMovingAverage="59.0"
num_200DayMovingAverage="52.8"
SharesOutstanding="78935000"
DividendDate="None"
ExDividendDate="None"
symbol="CRSP"
open="52.47"
high="52.81"
low="51.24"
price="51.35"
volume="1147230.00"
latest_trading_day="2023-08-03"
previous_close="53.01"
change="-1.66"
change_percent="-3.1315%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="25"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="75"
Volume_recent_avg="1231608"
Change_recent_avg="-0.09"
Delta_recent_avg="2.72"
Variance_recent_avg="1.36"
Change_ratio_recent_avg="-0.18"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="75"
Aroon_momentum_negative="25"
image_negative_thumbnail_id_1="1125"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0158.jpeg"
image_negative_thumbnail_id_2="1104"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0137.jpeg"
image_neutral_thumbnail_id_1="593"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0006.jpeg"
image_neutral_thumbnail_id_2="530"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_positive_thumbnail_id_1="703"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_positive_thumbnail_id_2="637"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0071.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1171"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
